Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04579666 · Apellis Pharmaceuticals, Inc. · PHASE2 · terminated · last registry update 2025-04-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study did not meet primary endpoint at Week 52. The study also did not meet key secondary efficacy endpoints. Pegcetacoplan (APL-2) was well tolerated in the study, and the data were consistent with the established safety profile.” | – | Registry record, Apellis Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against C3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-28Results posted on the registry: Swedish Orphan Biovitrum, Pegcetacoplan (NCT05148299)
- 2025-10-30Results posted on the registry: Swedish Orphan Biovitrum, Pegcetacoplan + Placebo matching Pegcetacoplan (NCT05096403)
- 2025-10-09Phase 3 first posted: Apellis Pharmaceuticals, Inc., APL-2, Pegcetacoplan (NCT07214740)
- 2025-08-06Results posted on the registry: Apellis Pharmaceuticals, Inc., Pegcetacoplan (NCT05067127)
- 2025-06-13Phase 3 first posted: Apellis Pharmaceuticals, Inc., Pegcetacoplan (NCT07020832)
- 2025-02-07Results posted on the registry: Apellis Pharmaceuticals, Inc., Pegcetacoplan (NCT04572854)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision